RT Journal Article
T1 Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.
A1 Partridge, Ann H
A1 Niman, Samuel M
A1 Ruggeri, Monica
A1 Peccatori, Fedro A
A1 Azim, Hatem A
A1 Colleoni, Marco
A1 Saura, Cristina
A1 Shimizu, Chikako
A1 Sætersdal, Anna Barbro
A1 Kroep, Judith R
A1 Mailliez, Audrey
A1 Warner, Ellen
A1 Borges, Virginia F
A1 Amant, Frédéric
A1 Gombos, Andrea
A1 Kataoka, Akemi
A1 Rousset-Jablonski, Christine
A1 Borstnar, Simona
A1 Takei, Junko
A1 Lee, Jeong Eon
A1 Walshe, Janice M
A1 Borrego, Manuel Ruíz
A1 Moore, Halle Cf
A1 Saunders, Christobel
A1 Cardoso, Fatima
A1 Susnjar, Snezana
A1 Bjelic-Radisic, Vesna
A1 Smith, Karen L
A1 Piccart, Martine
A1 Korde, Larissa A
A1 Goldhirsch, Aron
A1 Gelber, Richard D
A1 Pagani, Olivia
K1 Breast cancer
K1 Endocrine therapy
K1 Pregnancy desire
K1 Premenopausal women
K1 Treatment interruption
K1 Young women
AB Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5-10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study investigates the impact of temporary ET interruption to allow pregnancy. POSITIVE enrolled women with stage I-III HR + early breast cancer, ≤42 years, who had received 18-30 months of adjuvant ET and wished to interrupt ET for pregnancy. Treatment interruption for up to 2 years was permitted to allow pregnancy, delivery and breastfeeding, followed by ET resumption to complete the planned duration. From 12/2014 to 12/2019, 518 women were enrolled at 116 institutions/20 countries/4 continents. At enrolment, the median age was 37 years and 74.9 % were nulliparous. Fertility preservation was used by 51.5 % of women. 93.2 % of patients had stage I/II disease, 66.0 % were node-negative, 54.7 % had breast conserving surgery, 61.9 % had received neo/adjuvant chemotherapy. Tamoxifen alone was the most prescribed ET (41.8 %), followed by tamoxifen + ovarian function suppression (OFS) (35.4 %). A greater proportion of North American women were  The characteristics of participants in the POSITIVE study provide insights to which patients and doctors considered it acceptable to interrupt ET to pursue pregnancy. Similarities and variations from a regional, sociodemographic, disease and treatment standpoint suggest specific sociocultural attitudes across the world.
YR 2021
FD 2021-08-03
LK http://hdl.handle.net/10668/18376
UL http://hdl.handle.net/10668/18376
LA en
DS RISalud
RD Apr 7, 2025